Acute Porphyria Drug Database

H03BA02 - Propylthiouracil
Propably not porphyrinogenic
PNP

Rationale
Propylthiouracil is not metabolized by cyp-enzymes, nor does it induce or inhibit the activity of cyp-enzymes. Propylthiouracil has no potential porphyrogenic pharmacokinetic or pharmacodynamic properties.
Chemical description
Propylthiouracil is a thiourea anti thyroid drug. It inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine.
Therapeutic characteristics
Propylthiouracil is used in the management of hyperthyroidism. It is usually administered orally.
Metabolism and pharmacokinetics
Propylthiouracil undergoes rapid first-pass metabolism in the liver, and is mainly excreted in the urine as the glucuronic acid conjugate, with very little excreted as unchanged drug. It has an elimination half-life of 1-3 hours. Propylthiouracil is about 80% bound to plasma proteins. Propylthiouracil has no potential of pharmacokinetic drug interactions involving cyp-enzymes.
IPNet drug reports
Uneventful use reported in 2 patients with acute porphyria.

References

  1. Drug reference publications
  2. DrugBank. Propylthiouracil. #1592
  3. Sweetman SC, editor. Martindale: The complete drug reference. Propylthiouracil #1594
  4. Summary of Product Characteristics
  5. Swedish medicines agency. Summary of Product Characteristics (SPC) Tiotil. (05.09.2011). #1593

Similar drugs
Explore alternative drugs in similar therapeutic classes H03B / H03BA or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙